Pascal and Francis Bibliographic Databases

Help

Search results

Your search

au.\*:("KRIS, Mark G")

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 129

  • Page / 6
Export

Selection :

  • and

Docetaxel (Taxotere) in the treatment of non-small cell lung cancerKRIS, Mark G; MILLWARD, Michael.Seminars in oncology. 1999, Vol 26, Num 3, issn 0093-7754, 29 p., SUP10Serial Issue

New approaches in the treatment of non-small cell lung cancerKRIS, Mark G; TONATO, Maurizio.Lung cancer. 2002, Vol 38, issn 0169-5002, 50 p., SUP4Serial Issue

Docetaxel (taxotere) in combination with platinum-based regimens in non-small cell lung cancer : Results and future developmentsBELANI, C. P.Seminars in oncology. 1999, Vol 26, Num 3, pp 15-18, issn 0093-7754, SUP10Article

Docetaxel in the treatment of non-small cell lung, ovarian, and breast cancersHORTOBAGYI, Gabriel N; KRIS, Mark G.Seminars in oncology. 2002, Vol 29, Num 3, issn 0093-7754, 35 p., SUP12Serial Issue

Docetaxel (taxotere) in combination with vinorelbine in non-small cell lung cancerMILLER, V.Seminars in oncology. 1999, Vol 26, Num 3, pp 12-14, issn 0093-7754, SUP10Article

Docetaxel (taxotere) and neoadjuvant chemotherapy for non-small cell lung cancerMATTSON, K.Seminars in oncology. 1999, Vol 26, Num 3, pp 25-28, issn 0093-7754, SUP10Article

Chemotherapy for early stage non-small cell lung cancerKRIS, Mark G; AZZOLI, Christopher G.Lung cancer. 2001, Vol 34, pp S49-S52, issn 0169-5002, SUP3Conference Paper

Docetaxel (taxotere) and gemcitabine phase I and early phase II studies : Results to date and an overview of ongoing studiesVAN OOSTEROM, A. T.Seminars in oncology. 1999, Vol 26, Num 3, pp 8-11, issn 0093-7754, SUP10Article

First-line chemotherapy for NSCLC: an overview of relevant trialsBELANI, Chandra P; LANGER, Corey.Lung cancer. 2002, Vol 38, pp S13-S19, issn 0169-5002, SUP4Article

Lung cancer in US women: A contemporary epidemicPATEL, Jyoti D; BACH, Peter B; KRIS, Mark G et al.JAMA, the journal of the American Medical Association. 2004, Vol 291, Num 14, pp 1763-1768, issn 0098-7484, 6 p.Article

Meeting the chemotherapy needs of elderly and poor performance status patients with NSCLCGRIDELLI, Cesare; HAINSWORTH, John.Lung cancer. 2002, Vol 38, pp S37-S41, issn 0169-5002, SUP4Article

Perspectives and opportunities: Docetaxel in the current and future treatment of non-small cell lung cancerGREEN, Mark R.Seminars in oncology. 2002, Vol 29, Num 3, pp 17-21, issn 0093-7754, SUP12Article

Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancerBELANI, Chandra P.Seminars in oncology. 2002, Vol 29, Num 3, pp 4-9, issn 0093-7754, SUP12Article

Second line chemotherapy for NSCLC: establishing a gold standardFOSSELLA, Frank V; LYNCH, Thomas; SHEPHERD, Frances A et al.Lung cancer. 2002, Vol 38, pp S5-S12, issn 0169-5002, SUP4Article

Challenging the platinum combinations in the chemotherapy of NSCLCDOUILLARD, J.-Y; ECKARDT, J; SCAGLIOTTI, G. V et al.Lung cancer. 2002, Vol 38, pp S21-S28, issn 0169-5002, SUP4Article

Emerging role of docetaxel (taxotere) in advanced non-small cell lung cancerGANDARA, D. R; EDELMAN, M. J; LAU, D et al.Seminars in oncology. 1999, Vol 26, Num 3, pp 3-7, issn 0093-7754, SUP10Article

Weekly administration of docetaxel (taxotere) : Summary of clinical dataHAINSWORTH, J. D; BURRIS, H. A; GRECO, F. A et al.Seminars in oncology. 1999, Vol 26, Num 3, pp 19-24, issn 0093-7754, SUP10Article

Adjuvant and neoadjuvant treatments for NSCLCVOKES, Everett E; CHOY, Hak; GANDARA, David et al.Lung cancer. 2002, Vol 38, pp S29-S35, issn 0169-5002, SUP4Article

Docetaxel in ovarian cancer: Phase III perspectives and future developmentKAYE, Stanley B; VASEY, Paul A.Seminars in oncology. 2002, Vol 29, Num 3, pp 22-27, issn 0093-7754, SUP12Article

Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancerROSELL, Rafael; FOSSELLA, Frank; MILAS, Luka et al.Lung cancer. 2002, Vol 38, pp S43-S49, issn 0169-5002, SUP4Article

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung CancersYU, Helena A; ARCILA, Maria E; REKHTMAN, Natasha et al.Clinical cancer research (Print). 2013, Vol 19, Num 8, pp 2240-2247, issn 1078-0432, 8 p.Article

Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancersCHAFT, Jamie E; REKHTMAN, Natasha; SIMA, Camelia S et al.Cancer chemotherapy and pharmacology. 2013, Vol 72, Num 4, pp 931-934, issn 0344-5704, 4 p.Article

Driver Mutations Determine Survival in Smokers and Never-Smokers With Stage IIIB/IV Lung AdenocarcinomasPAIK, Paul K; JOHNSON, Melissa L; D'ANGELO, Sandra P et al.Cancer. 2012, Vol 118, Num 23, pp 5840-5847, issn 0008-543X, 8 p.Article

Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant CancersDOGAN, Snjezana; RONGLAI SHEN; LADANYI, Marc et al.Clinical cancer research (Print). 2012, Vol 18, Num 22, pp 6169-6177, issn 1078-0432, 9 p.Article

Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or GefitinibOXNARD, Geoffrey R; JANJIGIAN, Yelena Y; MILLER, Vincent A et al.Clinical cancer research (Print). 2011, Vol 17, Num 19, pp 6322-6328, issn 1078-0432, 7 p.Article

  • Page / 6